Exposure of Equipment and Utility Qualifications. Good Knowledge of Process Validation, Cleaning Validation. Management of QM5. Exposure of Stability and Artwork Management Analytical QA Handling of OOS, Risk Assessment, Self Inspection, APQR

Candidate should have experience with the GEA Granulation line, compression processes in the oncology sector, and coating with Glatt and ACG equipment. Experience in handling regulatory audits is a must. Proficiency in English communication is required.

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection.

First class MSc. in Chemistry Physical, Analytical, Organic, Inorganic or related fields and have qualified National Eligibility Test conducted by CSIR-UGC NET JRF, LS MHRD GATE

Diploma in Pharmacy from a recognized University, Institution. Should be a registered Pharmacist under the Pharmacy Act, 1948. 02 Years of experience in related field. Kalyan Singh Super Specialty Cancer Institute, Lucknow KSSSCI invites online applications from the citizens of India for direct recruitment on various Non-teaching posts

The candidate should have a strong interest in neuroscience, multi-tasking ability and be self-motivated. Expertise in live rodent surgery, RTPCR, western blot, immunohistochemistry, and basic biochemical assays is a MUST.

Malabar Cancer Centre, Thalassery (MCC) is an autonomous institution under Health and Family Welfare Department, Government of Kerala, established under Societies Registration Act XXI of 1860.

B.Pharma or 12th in Science PCB with D.Pharma and registered as Pharmacist under the Pharmacy Act 1948. Minimum 03 years wok experience.

M.Sc. in any field of Biology having good academic record with 60% and above marks will be preferred. The student having prior experience in handling of RNA, synthesis, gel purification as well as biophysical experimental techniques will be preferred.

Biomarker which is to be taken for further research, is an example of such a study. It also includes drug discovery and drug delivery systems, non-animal and animal models, organoids, organ on-chip, biomaterials and personalized medicine including immuno-therapeutics and genomic medicine. The scope also includes AI-ML algorithms for drug and biomarker discovery.

B. Pharm or 10+2 with Physics, Chemistry & Biology and Dip in Pharm. Min 3 years experience as a Pharmacist.

Execute and manage developmental project activities, participate in screening and generation of new opportunities in emerging drug delivery systems in order to contribute to the overall Research and Development goal of the organization.

Knowledge of 21 CFR Part 11, Annexure 11, CSV, GAMP 5, data integrity requirements for Pharma, Computer Software Assurance, IT systems and ITIL processes e.g. backup, restoration, infrastructure qualification, user access management etc, Pharma 4.0.

Execute, monitor, report and interpret preclinical, clinical and BABE studies at CROs to support various regulatory submissions within targeted timelines, budgets, quality and regulatory guidelines; identify health hazard and assess risks associated with pharmaceuticals, chemicals, intermediates, impurities, etc. by toxicological review and derivation

Establish long-term relationships with potential clients, partners, and distributors in the region to drive business growth. Lead negotiations and close deals related to contract manufacturing, development services, and out-licensing agreements.

Preparation of product wish list for Emerging Markets. Therapy analysis and portfolio analysis for identification of new products ideas. Identification of new growth segments, early market entry opportunities.

Presentation and communication of data to stakeholders, work in collaboration with the teams within and across the department. Ph.D in Life Sciences, Pharmacology, Biotechnology, Biological Engineering.

The National Health Mission has significantly contributed to improving India's public health outcomes through its relentless efforts in expanding human resources, addressing critical health issues, and fostering an integrated response to health emergencies. Over the last three years, the NHM has driven substantial progress in multiple areas, including maternal and child health, disease elimination, and healthcare infrastructure. The mission’s efforts have been integral to India's health improvements, particularly during the COVID-19 pandemic, and have played a vital role in ensuring more accessible and quality healthcare services across the country.